Bengaluru fake drug case: Assistant Drug Controller suspended for inspection lapses
The Department of Health and Family Welfare on Monday suspended Omkareshwar, Assistant Drug Controller with the Food Safety and Drug Administration (FDA) in Chamarajpet, Bengaluru, in connection with an investigation into counterfeit medicines.
Health Department officials said the action followed findings that he had failed to inspect the counterfeit drugs recovered from Krupa Healthcare, a distributor located near Minerva Circle within the Chamarajpet jurisdiction, and had not taken appropriate action against the distributor.
The case came to light after a Special Investigation Team (SIT) of the Bengaluru police, along with the FDA, arrested Veeresh Jain, the owner of Krupa Healthcare, on allegations of supplying fake medicines to hospitals, medical stores and clinics.
Investigators have said that Jain allegedly supplied counterfeit cancer drugs, life-saving medicines and intensive care unit (ICU) injections to more than 90 hospitals and clinics in the city, offering them at a discount of about 50 per cent.
Drug inspectors in Karnataka, as in other States, are responsible for licensing and inspecting drug manufacturing and distribution units under the Drugs and Cosmetics Act, 1940, and the rules framed under it. Their duties include checking whether stock is sourced from licensed suppliers, verifying bills and batch records, and initiating action when violations are found. The suspension of an Assistant Drug Controller is therefore a significant step in a case that touches on oversight of the city's medicine supply chain.
Regulation of medicines in India is shared between the Central Drugs Standard Control Organisation (CDSCO) and State drug control authorities. State authorities such as the FDA in Karnataka handle licensing of distributors and retail sales and carry out inspections within their jurisdiction, while the central body deals with approvals for new drugs and coordination on standards.
Counterfeit or falsified medicines are a concern because they may contain the wrong ingredients, incorrect doses, or no active ingredient at all. When the products involved are cancer drugs, life-saving medicines or ICU injections, the consequences can be serious for patients whose treatment depends on precise dosages and reliable quality. Hospitals and pharmacies are expected to buy only from licensed distributors and to keep records of the source of every batch, checks meant to prevent such products from reaching patients.
Public health experts have argued that the effectiveness of this system depends on the frequency and quality of inspections, and on timely action when violations are reported. In this instance, the alleged failure to inspect is itself the subject of the departmental action.
Officials have not said whether other employees of the firm, or other officials, are under scrutiny. The investigation by the SIT and the FDA is continuing. A suspension is a departmental measure and does not by itself establish guilt; both the suspended officer and the arrested owner retain the right to be presumed innocent unless a competent court finds otherwise.
The case has drawn attention to how medicines move from manufacturers to patients in a large city with a dense network of private hospitals, nursing homes and pharmacies. It also highlights the role of routine inspections, which regulators describe as a first line of defence against substandard and falsified drugs.
For patients, the practical advice from health authorities and doctors is to buy medicines from licensed pharmacies, insist on a proper bill, and report any suspicion about the quality of a medicine to the drug control authorities. Hospitals have also been urged to verify the credentials of their distributors.
Further details, including the outcome of the departmental inquiry and the police investigation, are awaited.
